search
Back to results

Cardiovascular Intervention Improvement Telemedicine Study

Primary Purpose

Cardiovascular Disease, Hypertension, Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pharmacist CVD
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiovascular Disease focused on measuring Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia, Adherence

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Enrolled in one of three Durham Veterans Affairs Medical Center (DVAMC) Primary Care Clinics affiliated with the hospital or the Raleigh Community-Based Outpatient Clinic (CBOC) for at least one year;
  • At least one visit to a primary care physician (PCP) at the Raleigh CBOC or Durham Veterans Affairs Medical Center (VAMC) associated primary care clinics in the previous 12 months;
  • Outpatient diagnostic code for hypertension and/or hypercholesterolemia and lab values indicating either poorly controlled BP levels (>150/90 Hg) AND/OR LDL (>130mg/dl) in the previous year.

Exclusion Criteria:

  • diagnosed with metastatic cancer,
  • diagnosed with dementia,
  • active diagnosis of psychosis,
  • treated with dialysis,
  • most recent creatinine lab level >2.5 or no creatinine lab value within past year
  • hospitalized for a stroke, heart attack, or had surgery for blocked arteries in the past 3 months,
  • participating in another interventional trial,
  • not currently receiving care at the Durham VAMC or the Raleigh CBOC
  • resident of a nursing home,
  • hard time seeing type/printing on books, magazines articles, etc.
  • hard time hearing on the telephone
  • limited/no access to telephone
  • plans to move medical care from DVAMC or Raleigh CBOC in next 12 months
  • CVD care is currently being managed by a clinical pharmacist
  • HbA1C value in the last 90day > 10% and patient is currently not on an insulin regimen.

Sites / Locations

  • Durham VA Medical Center, Durham, NC

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Arm 1

Arm 2

Arm Description

The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.

The education control group - these participants will receive educational material about CVD reduction.

Outcomes

Primary Outcome Measures

Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.

Secondary Outcome Measures

Mean Systolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Mean Systolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Mean Systolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Mean Diastolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Mean Diastolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Mean Diastolic Blood Pressure
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Medication Non-adherence
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Medication Non-adherence
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Medication Non-adherence
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Cholesterol LDL
Collected during interview visit by lab personnel
Cholesterol LDL
Collected during interview visit by lab personnel
Cholesterol LDL
Collected during interview visit by lab personnel
Body Mass Index
Calculated from vitals (height & weight) obtained during interview
Body Mass Index
Calculated from vitals (height & weight) obtained during interview
Body Mass Index
Calculated from vitals (height & weight) obtained during interview
HBA1C in Diabetic Patients
Lab values collected at interview visit by lab personnel
HBA1C in Diabetic Patients
Lab values collected at interview visit by lab personnel
HBA1C in Diabetic Patients
Lab values collected at interview visit by lab personnel

Full Information

First Posted
May 24, 2010
Last Updated
July 19, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT01142908
Brief Title
Cardiovascular Intervention Improvement Telemedicine Study
Official Title
Cardiovascular Intervention Improvement Telemedicine Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
November 1, 2011 (Actual)
Primary Completion Date
April 30, 2015 (Actual)
Study Completion Date
May 22, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have > 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.
Detailed Description
Anticipated Impacts on Veteran's Healthcare: Cardiovascular disease (CVD) is the leading cause of death in the U.S.; more than 80% of veterans have > 2 risk factors for CVD. An intervention that addresses multiple CVD risk factors among high-risk veterans has the greatest potential to improve morbidity and mortality. Project Background/Rationale: The proposed study will take place in two VA primary care clinics (1-Community-Based Outpatient Clinics and 1-primary care clinic affiliated with a hospital). We will improve CVD risk among veterans by addressing the modifiable risk factors of systolic blood pressure (SBP), smoking, and low-density lipoprotein cholesterol (LDL-C). The intervention will be tailored to the needs of vulnerable high risk patients (e.g. African Americans, low literate) and integrated into clinics, thereby enhancing the potential for benefit and generalizability to other settings. The proposed study could significantly improve CVD risk management among veterans for several reasons: 1) This intervention is a novel extension of our previous efficacious interventions, but provides a novel extension to address multiple chronic conditions contributing to CVD risk. 2) The intervention focuses on both multiple CVD-related behaviors and medication management. 3) The intervention was developed to ensure implementation across a large and representative sample of veterans; and; 4) The intervention, if found efficacious and financially self-sustaining, could be widely implemented within the VA healthcare system. Project Objectives: The proposed study will examine two research questions: Can patients randomized to a clinical pharmacist-administered telephone behavioral/ medication management intervention tailored to their needs improve CVD outcomes relative to a control group over 12 months? Primary Hypothesis: (H1) Veterans who receive the behavioral/medication intervention will have greater improvement of their CVD Risk Profile over the 12 months of follow-up as compared to the control group. Secondary Hypotheses: (H2) Veterans who receive the intervention will have improved medication adherence, physical activity, improved diet, lower body mass index as compared to the control group over 12 months of follow-up. (H3) Veterans who receive the intervention will have greater improvements in LDL over the 12 months of follow-up as compared to the control group. (H4) Veterans with diabetes who receive the intervention will have greater improved HbA1c as compared to the control group over 12 months of follow-up. If the intervention is found to be effective, is it cost effective? Project Methods: To address these hypotheses, we propose a two-arm randomized clinical trial design in which 500 patients with cardiovascular disease will be randomized to either the education control group or the intervention group. Patients randomized to the intervention group will receive a clinical pharmacist-administered intervention, which focuses on behavioral and a medication management. The intervention will occur over 12 months. Patients randomized to the control group will receive educational material about CVD reduction. Given the national prevalence of CVD and the dismal rates of risk factor control, intensive, but easily disseminated interventions such as the one proposed could significantly improve treatment of this epidemic in the VA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia
Keywords
Cardiovascular Disease, Hypertension, Diabetes, Hyperlipidemia, Adherence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
428 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Experimental
Arm Description
The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
Arm Title
Arm 2
Arm Type
No Intervention
Arm Description
The education control group - these participants will receive educational material about CVD reduction.
Intervention Type
Behavioral
Intervention Name(s)
Pharmacist CVD
Intervention Description
clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
Primary Outcome Measure Information:
Title
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Description
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time Frame
Baseline
Title
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Description
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time Frame
6 months
Title
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)
Description
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Mean Systolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
Baseline
Title
Mean Systolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
6 months
Title
Mean Systolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
12 months
Title
Mean Diastolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
Baseline
Title
Mean Diastolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
6 months
Title
Mean Diastolic Blood Pressure
Description
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Time Frame
12 months
Title
Medication Non-adherence
Description
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time Frame
Baseline
Title
Medication Non-adherence
Description
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time Frame
6 months
Title
Medication Non-adherence
Description
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Time Frame
12 months
Title
Cholesterol LDL
Description
Collected during interview visit by lab personnel
Time Frame
Baseline
Title
Cholesterol LDL
Description
Collected during interview visit by lab personnel
Time Frame
6 months
Title
Cholesterol LDL
Description
Collected during interview visit by lab personnel
Time Frame
12 months
Title
Body Mass Index
Description
Calculated from vitals (height & weight) obtained during interview
Time Frame
Baseline
Title
Body Mass Index
Description
Calculated from vitals (height & weight) obtained during interview
Time Frame
6 months
Title
Body Mass Index
Description
Calculated from vitals (height & weight) obtained during interview
Time Frame
12 months
Title
HBA1C in Diabetic Patients
Description
Lab values collected at interview visit by lab personnel
Time Frame
Baseline
Title
HBA1C in Diabetic Patients
Description
Lab values collected at interview visit by lab personnel
Time Frame
6 months
Title
HBA1C in Diabetic Patients
Description
Lab values collected at interview visit by lab personnel
Time Frame
12 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Enrolled in one of three Durham Veterans Affairs Medical Center (DVAMC) Primary Care Clinics affiliated with the hospital or the Raleigh Community-Based Outpatient Clinic (CBOC) for at least one year; At least one visit to a primary care physician (PCP) at the Raleigh CBOC or Durham Veterans Affairs Medical Center (VAMC) associated primary care clinics in the previous 12 months; Outpatient diagnostic code for hypertension and/or hypercholesterolemia and lab values indicating either poorly controlled BP levels (>150/90 Hg) AND/OR LDL (>130mg/dl) in the previous year. Exclusion Criteria: diagnosed with metastatic cancer, diagnosed with dementia, active diagnosis of psychosis, treated with dialysis, most recent creatinine lab level >2.5 or no creatinine lab value within past year hospitalized for a stroke, heart attack, or had surgery for blocked arteries in the past 3 months, participating in another interventional trial, not currently receiving care at the Durham VAMC or the Raleigh CBOC resident of a nursing home, hard time seeing type/printing on books, magazines articles, etc. hard time hearing on the telephone limited/no access to telephone plans to move medical care from DVAMC or Raleigh CBOC in next 12 months CVD care is currently being managed by a clinical pharmacist HbA1C value in the last 90day > 10% and patient is currently not on an insulin regimen.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hayden B Bosworth, PhD
Organizational Affiliation
Durham VA Medical Center, Durham, NC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Durham VA Medical Center, Durham, NC
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705-3875
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28192012
Citation
Goldstein KM, Stechuchak KM, Zullig LL, Oddone EZ, Olsen MK, McCant FA, Bastian LA, Batch BC, Bosworth HB. Impact of Gender on Satisfaction and Confidence in Cholesterol Control Among Veterans at Risk for Cardiovascular Disease. J Womens Health (Larchmt). 2017 Jul;26(7):806-814. doi: 10.1089/jwh.2016.5739. Epub 2017 Feb 13.
Results Reference
result
PubMed Identifier
28890128
Citation
Goldstein KM, Oddone EZ, Bastian LA, Olsen MK, Batch BC, Washington DL. Characteristics and Health Care Preferences Associated with Cardiovascular Disease Risk among Women Veterans. Womens Health Issues. 2017 Nov-Dec;27(6):700-706. doi: 10.1016/j.whi.2017.08.002. Epub 2017 Sep 8.
Results Reference
result
PubMed Identifier
29754649
Citation
Bosworth HB, Olsen MK, McCant F, Stechuchak KM, Danus S, Crowley MJ, Goldstein KM, Zullig LL, Oddone EZ. Telemedicine cardiovascular risk reduction in veterans: The CITIES trial. Am Heart J. 2018 May;199:122-129. doi: 10.1016/j.ahj.2018.02.002. Epub 2018 Feb 10.
Results Reference
result
PubMed Identifier
23537965
Citation
Melnyk SD, Zullig LL, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Stechuchak KM, Edelman D, Rakley S, Morey M, Bosworth HB. Telemedicine cardiovascular risk reduction in veterans. Am Heart J. 2013 Apr;165(4):501-8. doi: 10.1016/j.ahj.2012.08.005. Epub 2013 Feb 28.
Results Reference
result
PubMed Identifier
24303930
Citation
Zullig LL, Melnyk SD, Stechuchak KM, McCant F, Danus S, Oddone E, Bastian L, Olsen M, Edelman D, Rakley S, Morey M, Bosworth HB. The Cardiovascular Intervention Improvement Telemedicine Study (CITIES): rationale for a tailored behavioral and educational pharmacist-administered intervention for achieving cardiovascular disease risk reduction. Telemed J E Health. 2014 Feb;20(2):135-43. doi: 10.1089/tmj.2013.0145. Epub 2013 Dec 4.
Results Reference
result
PubMed Identifier
26011549
Citation
Zullig LL, Stechuchak KM, Goldstein KM, Olsen MK, McCant FM, Danus S, Crowley MJ, Oddone EZ, Bosworth HB. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm. 2015 Jun;21(6):479-85. doi: 10.18553/jmcp.2015.21.6.479.
Results Reference
result
PubMed Identifier
33769555
Citation
Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012675. doi: 10.1002/14651858.CD012675.pub3.
Results Reference
derived
PubMed Identifier
33688827
Citation
Ulmer CS, McCant F, Stechuchak KM, Olsen M, Bosworth HB. Prevalence of insomnia disorder and sleep apnea in a sample of veterans at risk for cardiovascular disease. J Clin Sleep Med. 2021 Jul 1;17(7):1441-1446. doi: 10.5664/jcsm.9228.
Results Reference
derived
PubMed Identifier
32685766
Citation
Zullig LL, Oakes MM, McCant F, Bosworth HB. Lessons learned from two randomized controlled trials: CITIES and STOP-DKD. Contemp Clin Trials Commun. 2020 Jul 8;19:100612. doi: 10.1016/j.conctc.2020.100612. eCollection 2020 Sep. Erratum In: Contemp Clin Trials Commun. 2020 Dec 10;20:100690.
Results Reference
derived
PubMed Identifier
25213741
Citation
Goldstein KM, Melnyk SD, Zullig LL, Stechuchak KM, Oddone E, Bastian LA, Rakley S, Olsen MK, Bosworth HB. Heart matters: Gender and racial differences cardiovascular disease risk factor control among veterans. Womens Health Issues. 2014 Sep-Oct;24(5):477-83. doi: 10.1016/j.whi.2014.05.005.
Results Reference
derived

Learn more about this trial

Cardiovascular Intervention Improvement Telemedicine Study

We'll reach out to this number within 24 hrs